Related Experiment Video
Updated: May 22, 2026

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples
Published on: July 28, 2016
Neutrophil dysfunction induced by hyperglycemia: modulation of myeloperoxidase activity
Cláudia de Souza Ferreira1, Tomaz Henrique Araújo, Marilene Lopes Ângelo
1Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, UNIFAL-MG, Alfenas, Minas Gerais, Brazil.
Abstract:
Our data suggest that impaired activity of myeloperoxidase (MPO) may play an important role in the dysfunction of neutrophils from hyperglycemic rats. Neutrophil biochemical pathways include the NADPH oxidase system and the MPO enzyme. They both play important role in the killing function of neutrophils. The effect of hyperglycemia on the activity of these enzymes and the consequences with regard to Candida albicans phagocytosis and the microbicidal property of rat peritoneal neutrophils is evaluated here. The NADPH oxidase system activity was measured using chemiluminescence and cytochrome C reduction assays. MPO activity was measured by monitoring HOCl production, and MPO protein expression was analysed using Western blot and immunofluorescence. C. albicans phagocytosis and death were evaluated by optical microscopy using the May-Grunwald-Giemsa staining method. ROS generation kinetic was slightly delayed in the diabetic group. MPO expression levels were higher in diabetic neutrophils; however, MPO activity was decreased in these same neutrophils compared with the controls. C. albicans phagocytosis and killing were lower in the diabetic neutrophils. Based on our experimental model, the phagocytic and killing functions of neutrophil phagocytosis are impaired in diabetic rats because of the decreased production of HOCl, highlighting the importance of MPO in the microbicidal function of neutrophils.
Insights
Hyperglycemia impairs neutrophil function in rats by decreasing myeloperoxidase (MPO) activity, which is crucial for killing Candida albicans. This leads to reduced phagocytic and microbicidal capabilities in diabetic neutrophils.
Area of Science:
- Immunology
- Biochemistry
- Microbiology
Background:
- Neutrophils are critical for host defense, employing enzymes like NADPH oxidase and myeloperoxidase (MPO) for microbial killing.
- Hyperglycemia, a hallmark of diabetes, is known to affect immune cell function, potentially compromising innate immunity.
Purpose of the Study:
- To investigate the impact of hyperglycemia on neutrophil enzyme activity, specifically NADPH oxidase and MPO.
- To evaluate the consequences of altered enzyme function on the phagocytosis and microbicidal activity against Candida albicans in a rat model.
Main Methods:
- Assessed NADPH oxidase activity using chemiluminescence and cytochrome C reduction.
- Measured MPO activity via HOCl production and analyzed MPO expression using Western blot and immunofluorescence.
- Evaluated Candida albicans phagocytosis and killing using microscopy and May-Grunwald-Giemsa staining.
Main Results:
- Neutrophils from hyperglycemic rats showed slightly delayed ROS generation kinetics.
- MPO expression was elevated, but MPO activity was significantly decreased in diabetic neutrophils.
- Phagocytosis and killing of Candida albicans were impaired in neutrophils from hyperglycemic rats.
Conclusions:
- Decreased MPO activity and subsequent reduced HOCl production contribute to impaired neutrophil phagocytic and microbicidal functions in hyperglycemic rats.
- Myeloperoxidase plays a vital role in the microbicidal capacity of neutrophils, and its dysfunction under hyperglycemia has significant implications for host defense.
Related Concept Videos
Hyperglycemia
Diabetic Neuropathy
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Hypoglycemia and Glucagon
Diabetic Foot Ulcer
Type II Diabetes II: Pathophysiology
